Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD. van Cruijsen H, et al. Among authors: hoekman k. Clin Dev Immunol. 2007;2007:17315. doi: 10.1155/2007/17315. Clin Dev Immunol. 2007. PMID: 18320010 Free PMC article. Clinical Trial.
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Among authors: hoekman k. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ. Vroling L, et al. Among authors: hoekman k. Angiogenesis. 2009;12(1):69-79. doi: 10.1007/s10456-009-9133-9. Epub 2009 Feb 11. Angiogenesis. 2009. PMID: 19212818 Free article.
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. van Cruijsen H, et al. Among authors: hoekman k. Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20061136 Clinical Trial.
118 results